These findings suggest that a combination of an NK-1 receptor antagonist and a 5-HT3 receptor antagonist, such as NEPA, may be a more suitable regimen for PONV prevention in patients undergoing VATS radical resection of lung cancer. This evidence concerns the gene TACR1 and lung cancer.